Vertex builds in gene editing yet again, with $1.2bn Arbor dealVertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of Share XVertex builds in gene editing yet again, with $1.2bn Arbor dealhttps://pharmaphorum.com/news/vertex-builds-in-gene-editing-yet-again-with-1-2bn-arbor-deal/
